alexa Biosimilars and Safety Issues | OMICS International
ISSN: 2167-1052
Advances in Pharmacoepidemiology and Drug Safety
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Biosimilars and Safety Issues

Eugenia Yiannakopoulou*

Department of Medical Laboratories, Highest Technological Educational Institute of Athens, Athens, Greece

*Corresponding Author:
Eugenia Yiannakopoulou
Department of Medical Laboratories
Faculty of Health and Caring Professions
Highest Technological Educational Institute of Athens
Leof El Venizelou 106
Kallithea 176 76, Athens, Greece
Tel: 0030 2109563791
E-mail: [email protected]

Received Date: July 06, 2017; Accepted Date: July 13, 2017; Published Date: July 19, 2017

Citation: Yiannakopoulou E (2017) Biosimilars and Safety Issues. Adv Pharmacoepidemiol Drug Saf 6:e143. doi: 10.4172/2167-1052.1000e143

Copyright: © 2017 Yiannakopoulou E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Advances in Pharmacoepidemiology and Drug Safety


Nowadays there is ongoing interest in the development of biosimilars, as biosimilars are anticipated to lead to price competition and to lower healthcare costs The first biosimilar, Omnitrope®, a biosimilar agent of the Recombinant Human Growth Hormone [rhGH]; was approved in Europe by the European Medicines Agency in 2006. Since then, 20 biosimilars have been approved in Europe including hematopoietic growth factors, insulin, monoclonal antibodies.

Biosimilars are biologics that are highly similar to approved biologics. According to European Medicines Agency, a biosimilar is a biological medicine that is similar to another biological medicine that has already been authorized for use. Thus, in contrast to generic drugs, biosimilars are similar but not identical to their reference products. Production of an identical copy of a biologic is quite difficult, due to a number of differences that exist between biologics and small molecules. Biologics are protein based drugs that can be thousands of times larger than small molecule drugs, are more complex and have higher immunogenic potential in comparison with small molecule drugs.

In addition, the manufacturing process for biologics is more complex and demanding in comparison with the manufacturing process for small molecule drugs. Multiple steps are required for cloning and protein expression, protein production, purification and validation. Some of these steps may vary between manufacturers resulting in differences between the biosimilar and the reference biologic drug. Small molecule drugs are manufactured through chemical reactions that can be safely reproduced by other manufactures leading to identical copies.

In clinical practice, at the moment, there is experience with the first monoclonal antibody biosimilar already approved the tumour necrosis factor-alpha inhibitor Remsima® (CT-P13). The drug has been approved for all the indications of the original drug infliximab (Remicade®). Approval of this biosimilar was based in part on extrapolation of clinical trial data from two indications (rheumatoid arthritis and ankylosing spondylitis) to all other indications, including inflammatory bowel disease [1,2]. Although the drug is available in a number of European countries since 2013, and it is currently prescribed for biologics naïve patients with inflammatory bowel disease, gastroenterologists express reservations about the extrapolation of indication and about the safety profile. A Postmarketing study of the biosimilar CT-P13 published from a Korean researcher’s reports tolerability and efficacy in patients treated for Crohn’s Disease and Inflammatory Bowel Disease and followed for 30 weeks. At the moment, there are ongoing clinical trials that investigate the clinical efficacy and safety profile of CT-P13 in inflammatory bowel disease. The example of CT-P13 reflects the impact of the approval of biosimilars in clinical practice.


In conclusion, the whole complexity in the manufacturing process of biosimilars renders the evaluation of the safety profile of biosimilars rather difficult. A regulatory pathway has been developed for the approval of biosimilars and this pathway is evolving. However, at the time of approval of a biosimilar agent, the knowledge on the safety profile of the agent is quite limited. Therefore extensive post-marketing surveillance is of paramount importance. Extrapolation of safety data from the reference product to the biosimilar is not straightforward.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 642
  • [From(publication date):
    August-2017 - Aug 19, 2018]
  • Breakdown by view type
  • HTML page views : 571
  • PDF downloads : 71

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A


[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


porn sex

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

Gaziantep Escort

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A


[email protected]

1-702-714-7001Extn: 9037


James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

mp3 indir

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals


Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T


[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7